Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
40.68 USD | -0.12% | +1.14% | +10.06% |
Financials (USD)
Sales 2024 * | 957M | Sales 2025 * | 1.09B | Capitalization | 5.17B |
---|---|---|---|---|---|
Net income 2024 * | 370M | Net income 2025 * | 484M | EV / Sales 2024 * | 6.67 x |
Net Debt 2024 * | 1.21B | Net Debt 2025 * | 426M | EV / Sales 2025 * | 5.14 x |
P/E ratio 2024 * |
13.5
x | P/E ratio 2025 * |
9.86
x | Employees | 373 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.92% |
Latest transcript on Halozyme Therapeutics, Inc.
1 day | -0.12% | ||
1 week | +1.14% | ||
Current month | +2.19% | ||
1 month | +2.49% | ||
3 months | +9.50% | ||
6 months | +3.91% | ||
Current year | +10.06% |
Managers | Title | Age | Since |
---|---|---|---|
Helen Torley
CEO | Chief Executive Officer | 61 | 14-01-05 |
Nicole LaBrosse
DFI | Director of Finance/CFO | 41 | 14-12-31 |
Mark Snyder
CMP | Compliance Officer | 57 | 22-01-02 |
Members of the board | Title | Age | Since |
---|---|---|---|
Connie Matsui
BRD | Director/Board Member | 70 | 06-07-30 |
Chairman | 59 | 15-08-04 | |
Barbara Duncan
BRD | Director/Board Member | 59 | 23-02-02 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
1.48% | 5 M€ | -1.80% | - | |
0.73% | 0 M€ | 0.00% | - | |
0.55% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 40.68 | -0.12% | 707,395 |
24-03-27 | 40.73 | +1.62% | 601,140 |
24-03-26 | 40.08 | -0.84% | 625,814 |
24-03-25 | 40.42 | +0.85% | 672,983 |
24-03-22 | 40.08 | -0.35% | 794,808 |
Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+10.06% | 5.17B | |
+2.73% | 108B | |
+9.59% | 103B | |
+6.58% | 23.48B | |
-12.59% | 21.93B | |
-3.29% | 19.68B | |
-35.36% | 18.37B | |
-13.29% | 16.33B | |
+4.68% | 13.72B | |
+34.25% | 12.15B |